CorMedix (CRMD) Investor Day 2026 summary

Strategic transformation and portfolio evolution

• Transitioned from a single-product, renal-focused company to a diversified specialty pharmaceutical platform with multiple commercial-stage drugs and a robust pipeline, following the Melinta acquisition and integration of new leadership roles.

• Completed acquisition of Melinta Therapeutics, expanding the portfolio with synergistic acute care assets and driving 2025 pro forma revenue above $400 million.

• Focused on organic growth, new indications, and leveraging a dynamic institutional platform for future expansion, while maintaining flexibility for synergistic business development.

• Announced a $75 million share repurchase program, reflecting confidence in undervalued shares and strong cash flow.

• Positioned for continued value creation through strategic business development and financial flexibility.

Financial guidance and performance

• FY 2025 pro forma net revenue exceeded $400 million, with DefenCath contributing ~$260 million during its peak TDAPA period and Melinta adding $140 million in pro forma revenue.

• FY 2026 revenue guidance is $300–320 million, with adjusted EBITDA expected at $100–125 million and a market cap approximately five times EBITDA.

• FY 2026 DefenCath sales projected at $100–140 million, with a rebound expected in 2027 as CMS increases dialysis bundle payments.

• Cash and short-term investments at year-end 2025 totaled $148 million, with $150 million in convertible debt.

Pipeline and commercial portfolio developments

• Expanded portfolio now centers on institutional injectable anti-infectives, with a focus on settings of care rather than specific therapeutic areas.

• REZZAYO (rezafungin) launched in 2023 for candidemia/invasive candidiasis, targeting a $250–350 million market and offering once-weekly dosing, broad-spectrum activity, and a favorable safety profile.

• Ongoing phase III RESPECT trial for REZZAYO in prophylaxis of invasive fungal disease in immunocompromised patients, with top-line results expected in Q2 2026; phase II studies underway for pneumocystis and aspergillosis.

• DefenCath is being advanced into the total parenteral nutrition (TPN) space, targeting prevention of CLABSI in a $500–$750 million addressable market, supported by the Nutriguard phase III trial.

• Multiple late-stage and preclinical programs in pipeline, including expansion into prophylaxis and pediatric hemodialysis.